Drug Discovery & Analog-Based Design
This foundational unit traces the entire lifecycle of a drug—from the initial spark of a ‘Hit’ molecule to its final launch as a marketed medicine. You will learn the diverse rational and serendipitous approaches that scientists use to discover ‘Lead’ compounds. The unit then dives deep into Analog-Based Drug Design, specifically mastering the powerful concept of Bioisosterism—the art of strategically swapping one chemical group for another to improve a drug’s safety, potency, or pharmacokinetic profile.
Syllabus & Topics
- 1Stages of Drug Discovery and Development: Target Identification: Identifying a specific biological protein/enzyme that causes the disease. Hit Identification: Screening millions of chemical compounds to find initial ‘Hits’ that interact with the target. Lead Optimization: Chemically modifying the hit molecule to drastically improve its potency, selectivity, and ADME properties to generate a ‘Lead’ compound. Preclinical Phase: Testing in animal models (in vivo) for safety and efficacy. Clinical Phases (1-3): Testing in healthy volunteers (Phase 1), small patient groups (Phase 2), and large-scale clinical trials (Phase 3). Regulatory Approval (NDA): Filing the massive dossier for FDA/CDSCO approval.
- 2Lead Discovery – Rational Approaches: Traditional Medicine: Mining centuries of ancient Ayurvedic, Chinese, and tribal knowledge for potent plant-based leads (e.g., Morphine from Opium, Quinine from Cinchona bark, Artemisinin from Qinghao). Random (High-Throughput) Screening: Robotically testing massive libraries of millions of random synthetic or natural compounds against a disease target without any prior knowledge about which might work (a ‘brute-force’ approach). Non-Random Screening: Intelligently focusing on specific chemical families already known to possess relevant biological activity.
- 3Lead Discovery – Other Approaches: Serendipitous Discovery: Finding drugs by pure accident. Classic examples: Penicillin (Alexander Fleming noticing mold killing bacteria on a contaminated petri dish), Viagra (originally developed for angina, clinicians accidentally observed its potent side effect). Lead from Drug Metabolism: Discovering that a metabolite (breakdown product) of a parent drug is itself more potent or less toxic than the original (e.g., Oxazepam, an active metabolite of Diazepam). Lead from Clinical Observations: Noting unexpected beneficial therapeutic effects during clinical trials for an entirely different disease.
- 4Analog-Based Drug Design & Bioisosterism: Once a lead compound is discovered, medicinal chemists systematically design ‘Analogs’ (structurally similar molecules) to optimize its properties. Bioisosterism: The core strategy. Replacing one chemical group (atom, function) on the lead molecule with another group that has similar physical, chemical, and electronic properties, but potentially improves a specific flaw (like toxicity, poor absorption, or rapid metabolism).
- 5Classification of Bioisosteres: Classical Bioisosteres (Grimm/Erlenmeyer): Groups with identical valence electron counts. Monovalent: -F, -OH, -NH₂, -CH₃ (all have approx. similar size/electronegativity). Divalent: -O-, -S-, -NH-, -CH₂-. Trivalent: -N=, -CH=, -P=. Ring Equivalents: Benzene ↔ Thiophene ↔ Pyridine. Non-Classical Bioisosteres: Groups that don’t share the same valence but mimic each other biologically. Examples: -COOH ↔ Tetrazole ring (both are acidic groups at physiological pH). -CONH₂ ↔ Sulfonamide (-SO₂NH₂).
- 6Case Studies in Bioisosteric Replacement: (1) Cimetidine → Ranitidine: Replacing the imidazole ring with a furan ring significantly reduced CNS side effects while maintaining H2 receptor antagonism. (2) Indomethacin → Sulindac: Replacing the -COOH group with a sulfinyl moiety created a prodrug that reduced gastrointestinal toxicity. (3) Losartan: Replacement of the carboxylic acid group with a tetrazole ring bioisostere maintained the critical acidity required for angiotensin receptor binding while drastically improving oral bioavailability.
Learning Objectives
Exam Prep Questions
Q1. Why is “Lead Optimization” considered the most critical stage in drug discovery?
Identifying an initial “hit” molecule during drug discovery is only the starting point. While the molecule may show strong activity against a biological target in laboratory tests, it often has major problems such as toxicity, poor solubility, low stability, or poor absorption in the body.
Lead optimization involves systematically modifying the chemical structure of the hit compound to improve its properties. Scientists create and test many related molecules (analogs) to enhance efficacy, safety, metabolic stability, and bioavailability. Through this iterative process, the crude hit compound is gradually refined into a lead candidate suitable for further development as a drug.
Q2. How is Viagra an example of “Serendipitous Drug Discovery”?
The drug Sildenafil, later marketed as Viagra, was originally investigated as a treatment for angina (chest pain caused by reduced blood flow to the heart).
During clinical trials, researchers observed that the drug had a different and unexpected physiological effect—it improved erectile function in male participants. Recognizing this unintended effect, the developers redirected the drug’s clinical development toward treating erectile dysfunction.
This discovery illustrates serendipity in drug development, where an unexpected observation leads to a major therapeutic breakthrough.
Q3. Why might a –COOH group be replaced with a tetrazole ring in drug design?
In medicinal chemistry, replacing one functional group with another that has similar chemical and biological properties is called bioisosteric replacement. Both a carboxylic acid group (–COOH) and a tetrazole ring behave as acidic groups at physiological pH, allowing them to interact with the same biological target.
However, carboxylic acid groups are often more susceptible to metabolic degradation, such as glucuronidation in the liver. Tetrazole rings tend to be more metabolically stable, which can improve a drug’s half-life, stability, and oral bioavailability while maintaining the required binding interactions with the target protein.